Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Long-Term Investments: 2018-2023

Historic Long-Term Investments for Rocket Pharmaceuticals (RCKT) over the last 1 years, with Dec 2023 value amounting to $34.3 million.

  • Rocket Pharmaceuticals' Long-Term Investments fell 20.70% to $34.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $34.3 million, marking a year-over-year decrease of 20.70%. This contributed to the annual value of $34.3 million for FY2023, which is 20.70% down from last year.
  • Per Rocket Pharmaceuticals' latest filing, its Long-Term Investments stood at $34.3 million for Q4 2023, which was up 18.52% from $29.0 million recorded in Q1 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Long-Term Investments peaked at $43.3 million during Q4 2022, and registered a low of $29.0 million during Q1 2023.
  • For the 2-year period, Rocket Pharmaceuticals' Long-Term Investments averaged around $35.5 million, with its median value being $34.3 million (2023).
  • Data for Rocket Pharmaceuticals' Long-Term Investments shows a maximum YoY declined of 20.70% (in 2023) over the last 5 years.
  • Rocket Pharmaceuticals' Long-Term Investments (Quarterly) stood at $43.3 million in 2022, then fell by 20.70% to $34.3 million in 2023.
  • Its last three reported values are $34.3 million in Q4 2023, $29.0 million for Q1 2023, and $43.3 million during Q4 2022.